Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero

Article Gastroenterology & Hepatology

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

Dan Turner et al.

Summary: STRIDE-II presents treatment targets for both adult and pediatric IBD, including long-term and short-term goals. These targets cover aspects such as clinical response, endoscopic healing, quality of life, and growth, providing guidance for improving patient outcomes.

GASTROENTEROLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease

Uma Mahadevan et al.

Summary: The study found that exposure to biologic, thiopurine, or combination therapy during pregnancy did not increase adverse maternal or fetal outcomes, and these treatments can be continued throughout pregnancy for women with IBD to maintain disease control.

GASTROENTEROLOGY (2021)

Add to Collection

Editorial Material Gastroenterology & Hepatology

ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease

T. Kucharzik et al.

JOURNAL OF CROHNS & COLITIS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study

Katarina Mitrova et al.

Summary: Vedolizumab demonstrates unique placental pharmacokinetics resulting in lower drug levels in cord blood compared to maternal blood at delivery, while ustekinumab shows a placental transfer pattern similar to anti-TNF agents.

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study

Pauline Wils et al.

Summary: This retrospective cohort study evaluated maternal and neonatal complications and management of vedolizumab or ustekinumab in pregnant women with IBD. The results showed that these drugs did not have negative effects on maternal or neonatal outcomes during pregnancy. Further prospective studies are needed to confirm these findings.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)

Add to Collection

Article Gastroenterology & Hepatology